This is a routine IP milestone with no near-term revenue or partnership catalyst. Monitor for patent grant and any subsequent licensing or collaboration announcements. Given the company's pre-revenue status and historical stock volatility, this event alone is unlikely to drive sustained price movement.
Price Chart
Executive Summary
Polyrizon announced that the European Patent Office has completed technical preparations for publication of its European patent application covering its Trap & Target mucoadhesive polymer technology for nasal drug delivery. This is a routine IP milestone for a development-stage company with no revenue, and the patent remains subject to examination and grant. The filing provides no financial data, no partnership, and no near-term commercialization catalyst.
Key Facts
- European patent application EP 4751737 titled 'Mucoadhesive Polymers for Nasal Drug Delivery' has been published by the EPO.
- The patent covers Polyrizon's Trap & Target (T&T) mucoadhesive polymer technology platform for nasal drug delivery.
- Polyrizon is a development-stage biotech company with no revenue from product sales.
- The patent application remains in examination; grant is not assured.
- No financial terms, partnership agreements, or commercialization timelines were disclosed.
Financial Impact
No financial impact disclosed; pre-revenue development-stage company.
Risk Factors
- Patent may not be granted or may issue in a narrower form than applied for.
- Company has no revenue and limited cash runway (per 20-F, 1,608,266 shares outstanding as of Dec 31, 2025).
- Forward-looking statements about market growth and partnering are aspirational with no concrete agreements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-067307 |
| Document: ea029428901ex99-1.htm | 0001213900-26-067307 |
| Document: 0001213900-26-067307-index-headers.html | 0001213900-26-067307 |
| Document: 0001213900-26-067307-index.html | 0001213900-26-067307 |
| Document: 0001213900-26-067307.txt | 0001213900-26-067307 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $9.67 $9.15 | ▼ −5.37% | ▼ −5.13% | $8.96 (−7.37%) |
Oct 2, 2026 24d ago | EFFECT | $9.61 $9.26 | ▲ +3.64% | ▲ +4.32% | $8.96 (+6.80%) |
Sep 22, 2026 4w ago | Press Release | $10.66 $11.16 | ▲ +4.69% | ▲ +5.41% | $8.96 (−15.98%) |
Sep 18, 2026 5w ago | F-1 | $10.90 $10.66 | ▲ +2.20% | ▲ +2.19% | $8.96 (+17.83%) |
Sep 4, 2026 7w ago | Press Release | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 6-K | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Sep 4, 2026 7w ago | 424B5 | $11.24 $11.15 | ▲ +0.80% | ▲ +0.25% | $8.96 (+20.31%) |
Aug 20, 2026 9w ago | 6-K | $10.30 $10.70 | ▲ +3.88% | ▲ +4.18% | $8.96 (−13.04%) |
Jul 13, 2026 15w ago | 6-K | $13.76 $13.07 | ▼ −4.98% | ▼ −5.38% | $8.96 (−34.88%) |
Jul 2, 2026 16w ago | 6-K | $13.80 $15.21 | ▲ +10.20% | ▲ +9.32% | $8.96 (−35.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers